Clinical Trial Update: SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide [Phase 3]

View source ↗

Summary

Phase 3 trial comparing SPI-2012 to Pegfilgrastim for neutropenia management in breast cancer patients receiving docetaxel and cyclophosphamide; study completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Neutropenia

Drugs mentioned

• Pegfilgrastim (pegfilgrastim)
• SPI-2012 (null)

Snippet

Sponsor: Spectrum Pharmaceuticals, Inc | Conditions: Neutropenia, Breast Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-03-02